Nischarin expression may have differing roles in male and female melanoma patients

• Published in: Journal of molecular medicine (Berlin, Germany) Germany), 2023-08, Vol.101 (8), p.1001-1014
• Main Authors: Ostojić, Marija, Jevrić, Marko, Mitrović-Ajtić, Olivera, Živić, Kristina, Tanić, Miljana, Čavić, Milena, Srdić-Rajić, Tatjana, Grahovac, Jelena
• Format: Article
• Language: English
• Subjects: Biomedical and Life Sciences; Biomedicine; Cell survival; DNA methylation; Females; Gene set enrichment analysis; Human Genetics; Internal Medicine; Localization; Males; Medical prognosis; Melanoma; Metastases; Molecular Medicine; Original Article; Ovarian cancer; Signal transduction; Tumor suppressor genes; Tumors
• ISSN: 0946-2716; 1432-1440
• DOI: 10.1007/s00109-023-02339-y

Due to the development of resistance to previously effective therapies, there is a constant need for novel treatment modalities for metastatic melanoma. Nischarin (NISCH) is a druggable scaffolding protein reported as a tumor suppressor and a positive prognostic marker in breast and ovarian cancers through regulation of cancer cell survival, motility and invasion. The aim of this study was to examine the expression and potential role of nischarin in melanoma. We found that nischarin expression was decreased in melanoma tissues compared to the uninvolved skin, and this was attributed to the presence of microdeletions and hyper-methylation of the NISCH promoter in the tumor tissue. In addition to the previously reported cytoplasmic and membranous localization, we observed nischarin in the nuclei in melanoma patients’ tissues. NISCH expression in primary melanoma had favorable prognostic value for female patients, but, unexpectedly, high NISCH expression predicted worse prognosis for males. Gene set enrichment analysis suggested significant sex-related disparities in predicted association of NISCH with several signaling pathways, as well as with different tumor immune infiltrate composition in male and female patients. Taken together, our results imply that nischarin may have a role in melanoma progression, but that fine-tuning of the pathways it regulates is sex-dependent. Key messages Nischarin is a tumor suppressor whose role has not been investigated in melanoma. Nischarin expression was downregulated in melanoma tissue compared to the normal skin. Nischarin had the opposite prognostic value in male and female melanoma patients. Nischarin association with signaling pathways differed in females and males. Our findings challenge the current view of nischarin as a universal tumor suppressor.